Biotech M&A · Q1 2026 Report
A summary of biotech and biopharma acquisitions announced in Q1 2026 — covering deal value, structure, therapeutic area, and what the tape is signalling about strategic priorities.
The quarter closed with 16 control transactions spanning public and private targets, with an acceleration in pace and deal size through March. Buyers are paying for approved products, near-commercial assets, and clear strategic platform fit — not broad early-stage optionality alone.
Report date: 08 April 2026
Q1 2026 snapshot
|
Total deals
16
Q1 2026
|
Disclosed value
~$44B
Total deal value
|
|
Largest deal
$7.8B
Arcellx & Centessa (tied)
|
Public targets
7 of 16
9 private targets
|
Market activity